Publication:
Fair and effective vaccine allocation during a pandemic

dc.contributor.coauthorErdoğan, Güneş
dc.contributor.coauthorYücel, Eda
dc.contributor.departmentDepartment of Industrial Engineering
dc.contributor.facultymemberYes
dc.contributor.kuauthorKiavash, Parinaz
dc.contributor.kuauthorSalman, Fatma Sibel
dc.contributor.schoolcollegeinstituteCollege of Engineering
dc.date.accessioned2024-12-29T09:39:49Z
dc.date.issued2024
dc.description.abstractThis paper presents a novel model for the Vaccine Allocation Problem (VAP), which aims to allocate the available vaccines to population locations over multiple periods during a pandemic. We model the disease progression and the impact of vaccination on the spread of the disease and mortality to minimise total expected mortality and location inequity in terms of mortality ratios under total vaccine supply and hospital and vaccination centre capacity limitations at the locations. The spread of the disease is modelled through an extension of the well -established Susceptible-Infected-Recovered (SIR) epidemiological model that accounts for multiple vaccine doses. The VAP is modelled as a nonlinear mixed -integer programming model and solved to optimality using the Gurobi solver. A set of scenarios with parameters regarding the COVID-19 pandemic in the UK over 12 weeks are constructed using a hypercube experimental design on varying disease spread, vaccine availability, hospital capacity, and vaccination capacity factors. The results indicate the statistical significance of vaccine availability and the parameters regarding the spread of the disease.
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.openaccessN/A
dc.description.peerreviewstatusN/A
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuTÜBİTAK
dc.description.sponsorshipThis work has been supported by Newton Fund Grant, UK 623795194 and TUBITAK grant, TR 220N017, which the authors gratefully acknowledge.
dc.description.studentonlypublicationNo
dc.description.studentpublicationYes
dc.description.versionN/A
dc.identifier.doi10.1016/j.seps.2024.101895
dc.identifier.eissn1873-6041
dc.identifier.embargoN/A
dc.identifier.grantno623795194
dc.identifier.grantnoTR 220N017
dc.identifier.issn0038-0121
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85192092622
dc.identifier.urihttps://doi.org/10.1016/j.seps.2024.101895
dc.identifier.urihttps://hdl.handle.net/20.500.14288/23116
dc.identifier.volume93
dc.identifier.wos001239761200001
dc.keywordsVaccine allocation
dc.keywordsCovid-19 pandemic
dc.keywordsFairness
dc.keywordsOptimisation
dc.keywordsNonlinear mixed integer program
dc.language.isoeng
dc.publisherElsevier
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofSocio-Economic Planning Sciences
dc.relation.openaccessN/A
dc.rightsN/A
dc.subjectEconomics
dc.subjectManagement
dc.subjectOperations research and management science
dc.titleFair and effective vaccine allocation during a pandemic
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorKiavash, Parinaz
local.contributor.kuauthorSalman, Fatma Sibel
relation.isGoalOfPublicationa9786601-9431-4553-9a46-013bb366fb87
relation.isGoalOfPublication.latestForDiscoverya9786601-9431-4553-9a46-013bb366fb87
relation.isOrgUnitOfPublicationd6d00f52-d22d-4653-99e7-863efcd47b4a
relation.isOrgUnitOfPublication.latestForDiscoveryd6d00f52-d22d-4653-99e7-863efcd47b4a
relation.isParentOrgUnitOfPublication8e756b23-2d4a-4ce8-b1b3-62c794a8c164
relation.isParentOrgUnitOfPublication.latestForDiscovery8e756b23-2d4a-4ce8-b1b3-62c794a8c164

Files